ArticleClinical rheumatology2026
Tacrolimus associated with lower infection risk compared to conventional immunosuppressants in systemic lupus erythematosus: real-world evidence.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveInfection remains a leading cause of mortality in systemic lupus erythematosus (SLE), this study aimed to evaluate the impact of tacrolimus (TAC) use on infection risk in SLE patients.
methodsA nested case-control study analyzed 3,176 SLE patients (1,509 infection cases; 1,667 controls) from SLE cohort (2010-2021). TAC exposure was defined as ≥ 30 consecutive days of use within 12 months preceding infection diagnosis or index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for associations between TAC use and infections risk. Drug combination effects of TAC was analyzed with cyclophosphamide (CYC), mycophenolate mofetil (MMF), hydroxychloroquine (HCQ), and glucocorticoids.
resultsAfter controlling for confounders (adjusted OR, 95% CI), TAC use was associated with a 60% lower overall infection risk versus other conventional immunosuppressants (0.40, 0.30-0.51), with stronger reductions in bacterial (0.50, 0.37-0.67) and skin/mucosal infections (0.30, 0.13-0.72). Significantly lower risks were observed at lower dosages (≤ 2 mg/d, OR 0.34, 0.24-0.47) and with prolonged use (> 365 days, OR 0.29, 0.19-0.46). Subgroup analyses confirmed enhanced protection in high-risk populations, such as severe disease activity (SLEDAI-2 K > 12, OR 0.32, 0.22-0.46) and CNS involvement (0.25, 0.09-0.71). TAC-HCQ co-therapy reduced infection risk (0.37, 0.27-0.52); separately, TAC counteracted glucocorticoid-associated risk (0.48, 0.30-0.77), and attenuated CYC/MMF-related risk (1.31, 0.83-2.06 vs. 4.25, 2.53-7.13 for CYC-MMF combinations).
conclusionsTAC offers superior infection prevention versus other conventional immunosuppressants in SLE, advocating for TAC-centered regimens to optimize risk-benefit profiles. Key Points • TAC use was associated with lower infection risk compared to other conventional immunosuppressants, particularly for bacterial infections and skin/mucosal infections. • Dose-response relationships were identified between both TAC dosage and duration of use and lower infection risk in SLE patients.
Indexed as
Identifiers
41261243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.